Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
At the conclusion of the inspection, the regulator had issued 11 observations to the facility. The company has now informed stock exchanges that the US FDA has determined the inspection classification status as OAI.
Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.
Ola Electric Mobility Ltd, Aster DM Healthcare Ltd, Data Patterns (India) Ltd and Shilpa Medicare Ltd are among the other losers in the BSE's 'A' group today, 15 June 2026.
Aurobindo Pharma Ltd lost 4.55% to Rs 1405.3 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 55749 shares were traded on the counter so far as against the average daily volumes of 50382 shares in the past one month.
Ola Electric Mobility Ltd tumbled 3.96% to Rs 43.92. The stock was the second biggest loser in 'A' group.On the BSE, 66.22 lakh shares were traded on the counter so far as against the average daily volumes of 125.03 lakh shares in the past one month.
Aster DM Healthcare Ltd crashed 3.15% to Rs 789.25. The stock was the third biggest loser in 'A' group.On the BSE, 42723 shares were traded on the counter so far as against the average daily volumes of 62252 shares in the past one month.
Data Patterns (India) Ltd pared 3.03% to Rs 4407.8. The stock was the fourth biggest loser in 'A' group.On the BSE, 71819 shares were traded on the counter so far as against the average daily volumes of 79760 shares in the past one month.
Shilpa Medicare Ltd dropped 2.52% to Rs 532.45. The stock was the fifth biggest loser in 'A' group.On the BSE, 45035 shares were traded on the counter so far as against the average daily volumes of 73771 shares in the past one month.
The counter rose 0.56% closed at Rs 1,472.25 on the BSE on Friday.
According to IQVIA MAT data for the 12 months ended April 2026, the US market for Tofacitinib tablets is estimated at approximately $494 million. Following this approval, Aurobindo Pharma has a total of 586 ANDA approvals from the USFDA, comprising 561 final approvals and 25 tentative approvals.
Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis, specifically in cases where patients have had an inadequate response or intolerance to prior standard therapies such as methotrexate or other disease-modifying antirheumatic drugs. In ulcerative colitis, the use also applies to patients who have not responded adequately or are intolerant to TNF (tumour necrosis factor) blockers.
Separately, the company inaugurated TheraNym, its dedicated biologics contract manufacturing organization (CMO), marking its entry into the biologics contract manufacturing segment. Located at Borapatla near Hyderabad, the facility is positioned as one of India's largest dedicated biologics CMOs.
Aurobindo Pharma said MSD (known as Merck & Co. in the US and Canada) will serve as the anchor customer for the facility, which has been established to support domestic and export supply requirements, subject to applicable approvals and customer requirements.
The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.
FDA has now determined that the inspection classification of this facility is “official action indicated” (OAI).
For the full year,net profit rose 0.54% to Rs 3504.75 crore in the year ended March 2026 as against Rs 3485.88 crore during the previous year ended March 2025. Sales rose 6.39% to Rs 33384.74 crore in the year ended March 2026 as against Rs 31378.13 crore during the previous year ended March 2025.
Suraksha Diagnostic Ltd lost 7.95% today to trade at Rs 294.5. The BSE Healthcare index is down 0.51% to quote at 47612.76. The index is up 9.48 % over last one month. Among the other constituents of the index, Max Healthcare Institute Ltd decreased 5.18% and Aurobindo Pharma Ltd lost 3.54% on the day. The BSE Healthcare index went up 11.99 % over last one year compared to the 7.03% fall in benchmark SENSEX.
Suraksha Diagnostic Ltd has added 4.27% over last one month compared to 9.48% gain in BSE Healthcare index and 4.15% drop in the SENSEX. On the BSE, 1019 shares were traded in the counter so far compared with average daily volumes of 3298 shares in the past one month. The stock hit a record high of Rs 353.65 on 26 Jun 2025. The stock hit a 52-week low of Rs 224.1 on 30 Mar 2026.
Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1541.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 23630.9. The Sensex is at 75137.86, down 0.24%. Aurobindo Pharma Ltd has gained around 8.46% in last one month.
Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 10.58% in last one month and is currently quoting at 24843.15, down 0.04% on the day. The volume in the stock stood at 4.58 lakh shares today, compared to the daily average of 12.95 lakh shares in last one month.
The benchmark May futures contract for the stock is quoting at Rs 1540, up 1.34% on the day. Aurobindo Pharma Ltd is up 29.73% in last one year as compared to a 3.98% slide in NIFTY and a 15.38% slide in the Nifty Pharma index.
The PE of the stock is 41.12 based on TTM earnings ending December 25.